Literature DB >> 21164105

Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells.

Gaia Spinetti1, Orazio Fortunato, Daniela Cordella, Paola Portararo, Nicolle Kränkel, Rajesh Katare, Graciela B Sala-Newby, Christine Richer, Marie-Pascale Vincent, Francois Alhenc-Gelas, Giancarlo Tonolo, Sara Cherchi, Costanza Emanueli, Paolo Madeddu.   

Abstract

RATIONALE: Homing of proangiogenic cells (PACs) is guided by chemoattractants and requires proteases to disrupt the extracellular matrix. The possibility that PAC recruitment involves an interaction between proteases and chemotactic factor receptors remains largely unexplored.
OBJECTIVE: To determine the role of human tissue kallikrein (hK1) in PAC invasion and its dependency on kinin receptor signaling. METHODS AND
RESULTS: Human mononuclear cells (MNCs) and culture-selected PACs express and release mature hK1 protein. HK1 gene (KLK1) silencing reduced PACs migratory, invasive, and proangiogenic activities. KLK1-knockout mouse bone marrow-derived MNCs showed similar impairments and were unable to support reparative angiogenesis in a mouse model of peripheral ischemia. Conversely, adenovirus-mediated KLK1 (Ad.KLK1) gene transfer enhanced PAC-associated functions, whereas the catalytically inactive variant R53H-KLK1 was ineffective. HK1-induced effects are mediated by a kinin B(2) receptor (B(2)R)-dependent mechanism involving inducible nitric oxide synthase and metalloproteinase-2 (MMP2). Lower hK1 protein levels were observed in PACs from type 2 diabetic (T2D) patients, whereas KLK1 mRNA levels were similar to those of healthy subjects, suggesting a post-transcriptional defect. Furthermore, B(2)R is normally expressed on T2D-PACs but remains uncoupled from downstream signaling. Importantly, whereas Ad.KLK1 alone could not restore T2D-PAC invasion capacity, combined KLK1 and B(2)R expression rescued the diabetic phenotype.
CONCLUSIONS: This study reveals new interactive components of the PACs invasive machinery, acting via protease- and kinin receptor-dependent mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21164105      PMCID: PMC3596779          DOI: 10.1161/CIRCRESAHA.110.236786

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  36 in total

1.  Targeting kinin B(1) receptor for therapeutic neovascularization.

Authors:  Costanza Emanueli; Maria Bonaria Salis; Tiziana Stacca; Gianfranco Pintus; Rudolf Kirchmair; Jeffrey M Isner; Alessandra Pinna; Leonardo Gaspa; Domenico Regoli; Cecile Cayla; João B Pesquero; Michael Bader; Paolo Madeddu
Journal:  Circulation       Date:  2002-01-22       Impact factor: 29.690

2.  Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases.

Authors:  C Hecquet; F Tan; B M Marcic; E G Erdös
Journal:  Mol Pharmacol       Date:  2000-10       Impact factor: 4.436

3.  Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway.

Authors:  J S Silvestre; S Bergaya; R Tamarat; M Duriez; C M Boulanger; B I Levy
Journal:  Circ Res       Date:  2001-10-12       Impact factor: 17.367

4.  Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice.

Authors:  P Meneton; M Bloch-Faure; A A Hagege; H Ruetten; W Huang; S Bergaya; D Ceiler; D Gehring; I Martins; G Salmon; C M Boulanger; J Nussberger; B Crozatier; J M Gasc; D Heudes; P Bruneval; T Doetschman; J Ménard; F Alhenc-Gelas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

5.  Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice.

Authors:  Mauro Siragusa; Rajesh Katare; Marco Meloni; Federico Damilano; Emilio Hirsch; Costanza Emanueli; Paolo Madeddu
Journal:  Circ Res       Date:  2010-01-07       Impact factor: 17.367

6.  Distinct kinin-induced functions are altered in circulating cells of young type 1 diabetic patients.

Authors:  Nicolle Kränkel; Stephen Paul Armstrong; Craig Alexander McArdle; Colin Dayan; Paolo Madeddu
Journal:  PLoS One       Date:  2010-06-17       Impact factor: 3.240

7.  Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation.

Authors:  Julie Chao; Hang Yin; Lin Gao; Makoto Hagiwara; Bo Shen; Zhi-Rong Yang; Lee Chao
Journal:  Hypertension       Date:  2008-09-02       Impact factor: 10.190

8.  Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle.

Authors:  C Emanueli; A Zacheo; A Minasi; J Chao; L Chao; M B Salis; T Stacca; S Straino; M C Capogrossi; P Madeddu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

9.  Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy.

Authors:  Dirk Westermann; Thomas Walther; Konstantinos Savvatis; Felcicitas Escher; Meike Sobirey; Alexander Riad; Michael Bader; Heinz-Peter Schultheiss; Carsten Tschöpe
Journal:  Diabetes       Date:  2009-03-10       Impact factor: 9.461

10.  Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential.

Authors:  Nicolle Kränkel; Rajesh G Katare; Mauro Siragusa; Luciola S Barcelos; Paola Campagnolo; Giuseppe Mangialardi; Orazio Fortunato; Gaia Spinetti; Nguyen Tran; Kai Zacharowski; Wojciech Wojakowski; Iwona Mroz; Andrew Herman; Jocelyn E Manning Fox; Patrick E MacDonald; Joost P Schanstra; Jean Loup Bascands; Raimondo Ascione; Gianni Angelini; Costanza Emanueli; Paolo Madeddu
Journal:  Circ Res       Date:  2008-10-16       Impact factor: 17.367

View more
  17 in total

1.  Tissue kallikrein promotes cardiac neovascularization by enhancing endothelial progenitor cell functional capacity.

Authors:  Yuyu Yao; Zulong Sheng; Yefei Li; Fengdi Yan; Cong Fu; Yongjun Li; Genshan Ma; Naifeng Liu; Julie Chao; Lee Chao
Journal:  Hum Gene Ther       Date:  2012-04-30       Impact factor: 5.695

2.  SERPINA4 is a novel independent prognostic indicator and a potential therapeutic target for colorectal cancer.

Authors:  Hui-Min Sun; Yu-Shuai Mi; Fu-Dong Yu; Yang Han; Xi-Sheng Liu; Su Lu; Yu Zhang; Sen-Lin Zhao; Ling Ye; Ting-Ting Liu; Dao-Hua Yang; Xiao-Feng Sun; Xue-Bin Qin; Zong-Guang Zhou; Hua-Mei Tang; Zhi-Hai Peng
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

3.  Genetic Analysis Reveals a Longevity-Associated Protein Modulating Endothelial Function and Angiogenesis.

Authors:  Francesco Villa; Albino Carrizzo; Chiara C Spinelli; Anna Ferrario; Alberto Malovini; Anna Maciąg; Antonio Damato; Alberto Auricchio; Gaia Spinetti; Elena Sangalli; Zexu Dang; Michele Madonna; Mariateresa Ambrosio; Leopoldo Sitia; Paolo Bigini; Gaetano Calì; Stefan Schreiber; Thomas Perls; Sergio Fucile; Francesca Mulas; Almut Nebel; Riccardo Bellazzi; Paolo Madeddu; Carmine Vecchione; Annibale A Puca
Journal:  Circ Res       Date:  2015-06-01       Impact factor: 17.367

4.  MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia.

Authors:  Gaia Spinetti; Orazio Fortunato; Andrea Caporali; Saran Shantikumar; Micol Marchetti; Marco Meloni; Betty Descamps; Ilaria Floris; Elena Sangalli; Rosa Vono; Ezio Faglia; Claudia Specchia; Gianfranco Pintus; Paolo Madeddu; Costanza Emanueli
Journal:  Circ Res       Date:  2012-12-11       Impact factor: 17.367

5.  Effects of a novel bradykinin B1 receptor antagonist and angiotensin II receptor blockade on experimental myocardial infarction in rats.

Authors:  Dongmei Wu; Xinchun Lin; Christian Bernloehr; Tobias Hildebrandt; Henri Doods
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 6.  Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.

Authors:  Ana Carolina B Stefanini; Bianca Rodrigues da Cunha; Tiago Henrique; Eloiza H Tajara
Journal:  Dis Markers       Date:  2015-12-09       Impact factor: 3.434

7.  Kallikrein gene-modified EPCs induce angiogenesis in rats with ischemic hindlimb and correlate with integrin αvβ3 expression.

Authors:  Shen Shen Fu; Fu Ji Li; Yuan Yuan Wang; An Bei You; Yi Liang Qie; Xiao Meng; Jian Rui Li; Bao Chuan Li; Yun Zhang; Qing Da Li
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

8.  miR-210 Enhances the Therapeutic Potential of Bone-Marrow-Derived Circulating Proangiogenic Cells in the Setting of Limb Ischemia.

Authors:  Marie Besnier; Stefano Gasparino; Rosa Vono; Elena Sangalli; Amanda Facoetti; Valentina Bollati; Laura Cantone; Germana Zaccagnini; Biagina Maimone; Paola Fuschi; Daniel Da Silva; Michele Schiavulli; Sezin Aday; Massimo Caputo; Paolo Madeddu; Costanza Emanueli; Fabio Martelli; Gaia Spinetti
Journal:  Mol Ther       Date:  2018-06-15       Impact factor: 11.454

9.  Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway.

Authors:  Gaia Spinetti; Daniela Cordella; Orazio Fortunato; Elena Sangalli; Sergio Losa; Ambra Gotti; Franco Carnelli; Francesco Rosa; Stefano Riboldi; Fausto Sessa; Elisa Avolio; Antonio Paolo Beltrami; Constanza Emanueli; Paolo Madeddu
Journal:  Circ Res       Date:  2012-12-18       Impact factor: 17.367

10.  Renal kallikrein activation and renoprotection after dual blockade of renin-angiotensin system in diet-induced diabetic nephropathy.

Authors:  Xia Zou; Xiao-xi Zhang; Xin-yu Liu; Rong Li; Min Wang; Wei-jie Wu; Yi Sui; Hai-lu Zhao
Journal:  J Diabetes Res       Date:  2015-03-30       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.